CA3026140A1 - Compositions and methods for treating metabolic diseases - Google Patents

Compositions and methods for treating metabolic diseases Download PDF

Info

Publication number
CA3026140A1
CA3026140A1 CA3026140A CA3026140A CA3026140A1 CA 3026140 A1 CA3026140 A1 CA 3026140A1 CA 3026140 A CA3026140 A CA 3026140A CA 3026140 A CA3026140 A CA 3026140A CA 3026140 A1 CA3026140 A1 CA 3026140A1
Authority
CA
Canada
Prior art keywords
polypeptide
subject
cmyr
serum
ntcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3026140A
Other languages
English (en)
French (fr)
Inventor
Hongli Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI HEP PHARMACEUTICAL Co Ltd
Original Assignee
SHANGHAI HEP PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI HEP PHARMACEUTICAL Co Ltd filed Critical SHANGHAI HEP PHARMACEUTICAL Co Ltd
Publication of CA3026140A1 publication Critical patent/CA3026140A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3026140A 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases Pending CA3026140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610370442.4 2016-05-30
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (1)

Publication Number Publication Date
CA3026140A1 true CA3026140A1 (en) 2017-12-07

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026140A Pending CA3026140A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Country Status (10)

Country Link
US (2) US11633454B2 (enExample)
EP (1) EP3463422B1 (enExample)
JP (1) JP7684788B2 (enExample)
KR (1) KR102627084B1 (enExample)
CN (1) CN109310737B (enExample)
AU (1) AU2017274094B2 (enExample)
CA (1) CA3026140A1 (enExample)
DK (1) DK3463422T3 (enExample)
ES (1) ES2979305T3 (enExample)
WO (1) WO2017206898A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130316B (zh) 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
DK2917231T3 (da) * 2012-11-12 2019-06-11 Univ Heidelberg Ruprecht Karls Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3204030B1 (en) 2014-10-07 2022-04-27 Myr GmbH Combination therapy of hbv and hdv infection
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv

Also Published As

Publication number Publication date
CN109310737A (zh) 2019-02-05
EP3463422A1 (en) 2019-04-10
JP7684788B2 (ja) 2025-05-28
AU2017274094A1 (en) 2019-02-14
US11633454B2 (en) 2023-04-25
ES2979305T3 (es) 2024-09-25
JP2019520341A (ja) 2019-07-18
EP3463422A4 (en) 2020-02-26
DK3463422T3 (da) 2024-07-22
KR20190015392A (ko) 2019-02-13
US20230414706A1 (en) 2023-12-28
CN109310737B (zh) 2023-05-05
US20200323951A1 (en) 2020-10-15
EP3463422B1 (en) 2024-05-22
AU2017274094B2 (en) 2020-09-10
KR102627084B1 (ko) 2024-01-19
WO2017206898A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
US20200338158A1 (en) Therapeutic Drug for Non-Alcoholic Fatty Liver Disease
AU2013366690B2 (en) Functionalized exendin-4 derivatives
US10925925B2 (en) Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors
CN106715466A (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
US20160272693A1 (en) Amylin analogues
US20240360194A1 (en) New Peptides as Potent and Selective GIP Receptor Agonists
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
KR20140071272A (ko) 항 당뇨병 펩타이드로서의 아포리포프로테인 ａｉｖ
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
US20250376498A1 (en) Fusion proteins comprising an improved glp-1 receptor agonist and uses thereof
US9340593B2 (en) Method of treating diabetes by a CTRP12 polypeptide
WO2018204918A1 (en) Treatment of hepatic disorders
TW202440649A (zh) 一種包含glp-1 融合蛋白的藥物製劑及其用途
CN117186206A (zh) 新型不同glp1类似肽共价聚合体及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526